{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:56:53Z","timestamp":1786222613597,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to assess the cost-effectiveness of sequential teriparatide\/zoledronic acid relative to zoledronic acid monotherapy for postmenopausal osteoporotic women in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A previously validated Markov microsimulation model was updated to examine the cost-effectiveness of daily subcutaneous teriparatide for 2 years followed by annual intravenous zoledronic acid for 3 years (sequential teriparatide\/zoledronic acid), compared with zoledronic acid monotherapy for 3 years in Chinese women with postmenopausal osteoporosis at ages 65, 70, 75, and 80 from the health care payer perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incremental cost-effectiveness ratios (ICERs) (US dollars [$] per quality-adjusted life-year [QALY]) of sequential teriparatide\/zoledronic acid vs. zoledronic acid monotherapy was $173,223\/QALY at age 65 years, which was much higher than the pre-determined willingness-to-pay (WTP) threshold of $ 31,512\/QALY, and the results were similar at other ages. In one-way sensitivity analyses, the two most impactful parameters were the cost of teriparatide and the residual effects of the medications included in this study. Sequential teriparatide\/zoledronic acid became cost-effective at age 80 with the cost of teriparatide reduced by 50%. Without the residual effect, the ICER increased to $257,982\/QALY. Probabilistic sensitivity analyses shown that the probabilities of zoledronic acid monotherapy being cost-effective were 100% at a WTP of $31,512\/QALY.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among Chinese women with postmenopausal osteoporosis, sequential teriparatide\/zoledronic acid was not cost-effective unless the cost of teriparatide was reduced by 50% only for the participants over 80 years.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.794861","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T05:26:35Z","timestamp":1645680395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness of Sequential Teriparatide\/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China"],"prefix":"10.3389","volume":"10","author":[{"given":"Ruxu","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/joim.12586","article-title":"Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project","volume":"281","author":"Katsoulis","year":"2017","journal-title":"J Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00198-012-2225-1","article-title":"Long-term mortality following fractures at different skeletal sites: a population-based cohort study","volume":"24","author":"Melton","year":"2013","journal-title":"Osteoporos Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2010.1360","article-title":"Atypical fractures as a potential complication of long-term bisphosphonate therapy","volume":"304","author":"Sellmeyer","year":"2010","journal-title":"JAMA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1359\/JBMR.051023","article-title":"Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis","volume":"21","author":"Tashjian","year":"2006","journal-title":"J Bone Miner Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1056\/NEJMe058154","article-title":"Combination and sequential therapy for osteoporosis","volume":"353","author":"Heaney","year":"2005","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","article-title":"New frontiers in osteoporosis therapy","volume":"71","author":"Cheng","year":"2020","journal-title":"Annu Rev Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone."},{"key":"B10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrendo.2015.134","article-title":"Bone: sequential osteoporosis treatment\u2013the order of things","volume":"11","author":"Abrahamsen","year":"2015","journal-title":"Nat Rev Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1210\/jc.2012-1844","article-title":"Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial","volume":"97","author":"Schafer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fphar.2020.00456","article-title":"Cost-effectiveness of zoledronic acid versus oral alendronate for postmenopausal osteoporotic women in China","volume":"11","author":"You","year":"2020","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"575893","DOI":"10.3389\/fphar.2020.575893","article-title":"Economic evaluation of oral alendronate therapy for osteoporosis in Chinese postmenopausal women: the impact of medication compliance and persistence","volume":"11","author":"You","year":"2020","journal-title":"Front Pharmacol."},{"key":"B14","volume-title":"China Guidelines for Pharmacoeconomic Evaluations, 2nd Edn","author":"Liu","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","article-title":"Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e10233","DOI":"10.1002\/jbm4.10233","article-title":"Cost-effectiveness of sequential teriparatide\/alendronate versus alendronate-alone strategies in high-risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide","volume":"3","author":"Mori","year":"2019","journal-title":"JBMR Plus."},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11657-021-00891-z","article-title":"Cost-effectiveness of sequential daily teriparatide\/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan","volume":"16","author":"Mori","year":"2021","journal-title":"Arch Osteoporos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3969\/j.issn.1006-7108","article-title":"Guidelines for the diagnosis and management of primary osteoporosis","volume":"25","year":"2019","journal-title":"Chin J Osteoporos"},{"key":"B21","unstructured":""},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00198-016-3502-1","article-title":"Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study","volume":"27","author":"Si","year":"2016","journal-title":"Osteoporos Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11136-010-9762-x","article-title":"Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey (2008)","volume":"20","author":"Sun","year":"2011","journal-title":"Qual Life Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00198-014-2636-2","article-title":"A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions","volume":"25","author":"Si","year":"2014","journal-title":"Osteoporosis Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","article-title":"Utility values associated with osteoporotic fracture: a systematic review of the literature","volume":"82","author":"Hiligsmann","year":"2008","journal-title":"Calcif Tissue Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00774-013-0484-3","article-title":"Hip fractures in Hefei, China: the Hefei osteoporosis project","volume":"32","author":"Wang","year":"2014","journal-title":"J Bone Miner Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00198-011-1627-9","article-title":"Ethnic difference of clinical vertebral fracture risk","volume":"23","author":"Bow","year":"2012","journal-title":"Osteoporos Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00198-007-0499-5","article-title":"Epidemiology of distal forearm fractures in Oslo, Norway","volume":"19","author":"Lofthus","year":"2008","journal-title":"Osteoporos Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-016-3772-7","article-title":"Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA","volume":"28","author":"Mori","year":"2017","journal-title":"Osteoporos Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","article-title":"Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis","volume":"27","author":"Kanis","year":"2000","journal-title":"Bone."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Intern Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"Kanis","year":"2003","journal-title":"Bone."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e80890","DOI":"10.1371\/journal.pone.0080890","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye","year":"2019","journal-title":"BMJ Open."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-017-3940-4","article-title":"Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan","volume":"28","author":"Mori","year":"2017","journal-title":"Osteoporos Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","article-title":"Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture","volume":"49","author":"Hiligsmann","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"B41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","article-title":"Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium","volume":"29","author":"Hiligsmann","year":"2011","journal-title":"Pharmacoeconomics."},{"key":"B42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s001980050113","article-title":"Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time","volume":"9","author":"Melton","year":"1999","journal-title":"Osteoporos Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00198-014-2699-0","article-title":"The economic burden of fracture patients with osteoporosis in western China","volume":"25","author":"Qu","year":"2014","journal-title":"Osteoporos Int."},{"key":"B44","unstructured":""},{"key":"B45","unstructured":""},{"key":"B46","volume-title":"China Health Statistical Yearbook","year":"2020"},{"key":"B47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11657-021-00956-z","article-title":"Cost-effectiveness of zoledronic acid compared with sequential denosumab\/alendronate for older osteoporotic women in Japan","volume":"16","author":"Mori","year":"2021","journal-title":"Arch Osteoporos."},{"key":"B49","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","article-title":"Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective","volume":"50","author":"Hiligsmann","year":"2020","journal-title":"Semin Arthritis Rheum."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.794861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T05:26:41Z","timestamp":1645680401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.794861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":49,"alternative-id":["10.3389\/fpubh.2022.794861"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.794861","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"article-number":"794861"}}